- Glycemic Control Is Associated with Histological Findings of Nonalcoholic Fatty Liver Disease
-
Miyake T, Furukawa S, Matsuura B, Yoshida O, Miyazaki M, Shiomi A, Kanamoto A, Nakaguchi H, Nakamura Y, Imai Y, Koizumi M, Watanabe T, Yamamoto Y, Koizumi Y, Tokumoto Y, Hirooka M, Kumagi T, Takesita E, Ikeda Y, Abe M, Hiasa Y
- KMID: 2555775
- Diabetes Metab J.
- 2024 May;48(3):440-448.
- doi: 10.4093/dmj.2023.0200
Background: Poor lifestyle habits may worsen nonalcoholic fatty liver disease (NAFLD), with progression to nonalcoholic steatohepatitis (NASH) and cirrhosis. This study investigated the association between glycemic control status and hepatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
-
Liu C, You H, Zeng QL, Wong YJ, Wang B, Grgurevic I, Liu C, Yim HJ, Gou W, Dong B, Ju S, Guo Y, Yu Q, Hirooka M, Enomoto H, Hanafy AS, Cao Z, Dong X, LV J, Kim TH, Koizumi Y, Hiasa Y, Nishimura T, Iijima H, Xu C, Dai E, Lan X, Lai C, Liu S, Wang F, Guo Y, Lv J, Zhang L, Wang Y, Xie Q, Shao C, Liu Z, Ravaioli F, Colecchia A, Li J, Teng GJ, Qi X
- KMID: 2563414
- Clin Mol Hepatol.
- 2025 Jan;31(1):105-118.
- doi: 10.3350/cmh.2024.0198
Backgrounds/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol... -
- CITED
-
- Close
- SHARE
-
- Close
